Stoke Therapeutics, Inc. (STOK) — Analyst outlook / Analyst consensus target is. Based on 15 analyst ratings, the consensus is bullish — 12 Buy, 3 Hold.
The consensus price target is $42.75 (low: $35.00, high: $60.00), representing an upside of 19.2% from the current price $35.86.
Analysts estimate Earnings Per Share (EPS) of $-2.02 and revenue of $0.02B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.65 vs est $-2.02 (beat +18.2%). 2025: actual $-0.12 vs est $-0.09 (missed -35.8%). Analyst accuracy: 76%.
STOK Stock — 12-Month Price Forecast
$42.75
▲ +19.21% Upside
Average Price Target
Based on 15 Wall Street analysts offering 12-month price targets for Stoke Therapeutics, Inc., the average price target is $42.75, with a high forecast of $60.00, and a low forecast of $35.00.
The average price target represents a +19.21% change from the last price of $35.86.
Highest Price Target
$60.00
Average Price Target
$42.75
Lowest Price Target
$35.00
STOK Analyst Ratings
Buy
Based on 15 analysts giving stock ratings to Stoke Therapeutics, Inc. in the past 3 months
EPS Estimates — STOK
76%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$1.65
vs Est –$2.02
▲ 22.3% off
2025
Actual –$0.12
vs Est –$0.09
▼ 26.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — STOK
74%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.037B
vs Est $0.018B
▲ 51.0% off
2025
Actual $0.184B
vs Est $0.184B
▲ 0.1% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
